Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Launch of 14 New Cancer Gene Panels

Published: Wednesday, July 16, 2014
Last Updated: Wednesday, July 16, 2014
Bookmark and Share
QIAGEN introduces 14 new panels for targeted enrichment of up to 570 clinically-relevant genes, expands largest portfolio of panels for assessing cancer genes.

QIAGEN N.V. has announced the launch of 14 new GeneRead™ DNAseq V2 gene panels targeting an extensive range of cancer-related genes or gene regions. Gene panels are an integral part of many next-generation sequencing (NGS) workflows. They are used to enrich genes of interest in a sample prior to sequencing runs and as such can be seen as the core assay in the workflow.

QIAGEN’s new GeneRead panels are customizable to include other genes or gene regions of clinical or biological interest and are compatible with any NGS sequencer. They are part of QIAGEN’s industry-leading sample-to-library workflows, which are helping to drive the growing use of NGS in clinical applications.

“By delivering high-quality solutions for sample processing, assay design and data analysis and interpretation, QIAGEN is addressing the key bottlenecks of current sequencing workflows, making NGS technology more effective, robust and scalable. We today offer the largest collection of gene panels in the market and are rapidly expanding our portfolio of high-utility solutions that help labs create fast and integrated workflows,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “The new GeneRead panels incorporate sophisticated algorithms to enable analysis of many gene variants and customization for specific objectives. We continue to deliver on QIAGEN’s growth driver of providing universal solutions for NGS workflows by addressing our customers’ urgent needs for fast turnaround times, low DNA input requirements, and quality control to ensure accurate, reproducible results.”

The 14 new GeneRead DNAseq V2 panels cover an extensive range of cancer-related genes and gene regions, including “focused” panels each targeting 8-25 genes, “disease-specific” panels for 40-50 genes, and “comprehensive” panels for as many as 160 genes. The content of the panels has been developed based on the latest recommendations from relevant medical and scientific literature.

The gene panels are integrated with QIAGEN’s industry-leading bioinformatics software, Ingenuity® Variant Analysis™, an extensive, curated database of gene variants and clinical data that enables interpretation of NGS results and delivers valuable insights from sequencing data. Laboratories also can customize GeneRead panels for specific disease pathways or research needs by tapping into QIAGEN’s deep molecular content portfolio through GeneGlobe, an online portal covering more than 60,000 annotated molecular assays.

QIAGEN has been collaborating with selected customers in the development of the new gene panels to validate product performance in a wide range of applications, including translational research and clinical applications. Dr. Gregory J. Tsongalis, Professor and Director of Molecular Pathology at the Department of Pathology at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, one of the early users of QIAGEN’s GeneRead V2 panels, commented: "For focused analysis of relevant genes or gene regions in our targeted oncology studies, we found that the pre-validated GeneRead gene panels are robust and have very streamlined workflows. These gene panels are capable of generating sequencing data from the most difficult of tissue samples. The cloud-based bioinformatics resources are very helpful in the interpretation of the data.”

QIAGEN’s GeneRead technology provides the most cost-effective, time-efficient approach for target enrichment in preparation for NGS runs on any sequencer. Unlike other approaches for sequencers, GeneRead panels use as little as 10 nanograms of starting DNA material per pool. They are compatible with FFPE samples and do not require any specialized instruments. The proprietary algorithms and chemistry provide industry leading coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases are covered by at least 20% of the mean coverage depth) for the targeted DNA sequencing. In addition to their quality advantages, QIAGEN gene panels require only three hours to enrich for targets and provide for a substantially reduced time to go from isolated DNA sample to sequencing-ready libraries.

QIAGEN provides a full range of sample technologies, assay panels and library preparation products which today generate substantial revenue and solve important NGS needs in clinical and clinical research applications in particular. QIAGEN also is developing the benchtop GeneReader™ NGS platform for the same applications. Combined with QIAGEN’s existing NGS portfolio, GeneReader is designed to provide a seamless automated workflow from biological sample, through DNA preparation, enrichment, library preparation, sequencing, data analysis and interpretation, to deliver valuable insights into diseases.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN Receives FDA Approval for CMV Assay
Assay offers faster quantification of CMV DNA levels in patient samples.
Friday, June 20, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Integrates Content from BIOBASE
The new content expands the world’s most comprehensive, high-quality and up-to-date literature source for clinical research and diagnosis.
Wednesday, May 21, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Acquires Ingenuity Systems
Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics.
Thursday, May 02, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Unveils Initiative to Create Next-generation Sequencing Portfolio
Company plans to offer sample-to-result workflows that integrate its sample preparation and assay products with a next-generation benchtop sequencer and new bioinformatics.
Tuesday, June 26, 2012
QIAGEN Receives FDA Clearances for Rotor-Gene Q MDx Instrument and Compatible Influenza A/B Assay
Both products receive 510(k) clearance for in vitro diagnostic use in the U.S..
Tuesday, April 17, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN and Genome Diagnostics Expands Partnership to Develop Tests for Applications in Prevention and Personalized Healthcare
Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases.
Friday, June 18, 2010
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!